

# Roberto Cilia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3348544/publications.pdf>

Version: 2024-02-01

106  
papers

5,868  
citations

61857

43  
h-index

82410

72  
g-index

107  
all docs

107  
docs citations

107  
times ranked

7981  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical correlates of serum 25-hydroxyvitamin D in Parkinson's disease. <i>Nutritional Neuroscience</i> , 2022, 25, 1128-1136.	1.5	11
2	Short- and long-term motor outcome of STN-DBS in Parkinson's Disease: focus on sex differences. <i>Neurological Sciences</i> , 2022, 43, 1769-1781.	0.9	15
3	Role of Lysosomal Gene Variants in Modulating GBA-Associated Parkinson's Disease Risk. <i>Movement Disorders</i> , 2022, 37, 1202-1210.	2.2	17
4	Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy from Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 1272-1281.	2.2	17
5	Cerebrospinal fluid neuropathological biomarkers in beta-propeller protein-associated neurodegeneration, with complicated parkinsonian phenotype. <i>Parkinsonism and Related Disorders</i> , 2022, 98, 38-40.	1.1	0
6	Low Prevalence of NOTCH2NLC GGC Repeat Expansion in White Patients with Movement Disorders. <i>Movement Disorders</i> , 2021, 36, 251-255.	2.2	23
7	Does Gut Microbiota Influence the Course of Parkinson's Disease? A 3-Year Prospective Exploratory Study in de novo Patients. <i>Journal of Parkinson's Disease</i> , 2021, 11, 159-170.	1.5	27
8	Uncovering Levodopa-Responsive Dystonic Tremor after Midbrain Stroke. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 980-982.	0.8	1
9	Levodopa-carbidopa intrajejunal infusion in Parkinson's disease: untangling the role of age. <i>Journal of Neurology</i> , 2021, 268, 1728-1737.	1.8	9
10	Parkinsonism and Nigrostriatal Damage Secondary to CSF1R-Related Primary Microgliopathy. <i>Movement Disorders</i> , 2020, 35, 2360-2362.	2.2	6
11	Saposin D variants are not a common cause of familial Parkinson's disease among Italians. <i>Brain</i> , 2020, 143, e71-e71.	3.7	7
12	Inhibitory control dysfunction in parkinsonian impulse control disorders. <i>Brain</i> , 2020, 143, 3734-3747.	3.7	13
13	Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. <i>Journal of Neurology</i> , 2020, 267, 2949-2960.	1.8	26
14	Skin Biopsy May Help to Distinguish Multiple System Atrophy from Parkinson's Disease With Orthostatic Hypotension. <i>Movement Disorders</i> , 2020, 35, 1649-1657.	2.2	50
15	Could <i>Mucuna pruriens</i> be the answer to Parkinson's disease management in sub-Saharan Africa and other low-income countries worldwide?. <i>Parkinsonism and Related Disorders</i> , 2020, 73, 3-7.	1.1	16
16	The gut microbiome in Parkinson's disease: A culprit or a bystander?. <i>Progress in Brain Research</i> , 2020, 252, 357-450.	0.9	70
17	Telemedicine for parkinsonism: A two-step model based on the COVID-19 experience in Milan, Italy. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 130-132.	1.1	30
18	Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinson's Disease and Atypical Parkinsonisms. <i>Frontiers in Neuroscience</i> , 2020, 14, 624.	1.4	17

#	ARTICLE	IF	CITATIONS
19	Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa. <i>Brain</i> , 2020, 143, 2490-2501.	3.7	87
20	Î±-Synuclein oligomers in skin biopsy of idiopathic and monozygotic twin patients with Parkinson's disease. <i>Brain</i> , 2020, 143, 920-931.	3.7	41
21	Effects of COVID-19 on Parkinson's Disease Clinical Features: A Community-Based Case-Control Study. <i>Movement Disorders</i> , 2020, 35, 1287-1292.	2.2	148
22	The SPID-GBA study. <i>Neurology: Genetics</i> , 2020, 6, e523.	0.9	37
23	Nutritional characterisation of Zambian <i>Moringa oleifera</i> : acceptability and safety of short-term daily supplementation in a group of malnourished girls. <i>International Journal of Food Sciences and Nutrition</i> , 2019, 70, 107-115.	1.3	21
24	Resting state oscillations suggest a motor component of Parkinson's Impulse Control Disorders. <i>Clinical Neurophysiology</i> , 2019, 130, 2065-2075.	0.7	4
25	Monitoring subthalamic oscillations for 24 hours in a freely moving Parkinson's disease patient. <i>Movement Disorders</i> , 2019, 34, 757-759.	2.2	28
26	Effects of liraglutide in the treatment of severe obesity in a young patient with parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2019, 405, 309.	0.3	1
27	Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism. <i>Movement Disorders</i> , 2019, 34, 396-405.	2.2	252
28	Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. <i>Movement Disorders</i> , 2019, 34, 9-21.	2.2	73
29	Daily intake of <i>Mucuna pruriens</i> in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 60-66.	1.1	39
30	Opioid K receptor variant is associated with a delayed onset of dyskinesias in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 323-324.	0.9	1
31	Molecular Imaging of the Cannabinoid System in Idiopathic Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018, 141, 305-345.	0.9	16
32	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. <i>Movement Disorders</i> , 2017, 32, 181-192.	2.2	88
33	Efficacy of rasagiline and selegiline in Parkinson's disease: a head-to-head 3-year retrospective case-control study. <i>Journal of Neurology</i> , 2017, 264, 1254-1263.	1.8	52
34	<i>DNAJC12</i> and dopa-responsive nonprogressive parkinsonism. <i>Annals of Neurology</i> , 2017, 82, 640-646.	2.8	60
35	<i>Mucuna pruriens</i> in Parkinson disease. <i>Neurology</i> , 2017, 89, 432-438.	1.5	79
36	Magnetic Resonance Parkinsonism Index: diagnostic accuracy of a fully automated algorithm in comparison with the manual measurement in a large Italian multicentre study in patients with progressive supranuclear palsy. <i>European Radiology</i> , 2017, 27, 2665-2675.	2.3	66

#	ARTICLE	IF	CITATIONS
37	Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile. <i>Journal of the Neurological Sciences</i> , 2016, 365, 175-180.	0.3	44
38	Survival and dementia in <i>GBA</i> -associated Parkinson's disease: <i>T</i> mutation matters. <i>Annals of Neurology</i> , 2016, 80, 662-673.	2.8	312
39	Tryptophan hydroxylase type 2 variants modulate severity and outcome of addictive behaviors in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 29, 96-103.	1.1	26
40	Dementia in Parkinson's disease: Is male gender a risk factor?. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 67-72.	1.1	52
41	Long-term cognitive follow-up of Parkinson's disease patients with impulse control disorders. <i>Movement Disorders</i> , 2015, 30, 696-704.	2.2	35
42	Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. <i>Journal of Neural Transmission</i> , 2015, 122, 799-808.	1.4	7
43	Parkinson's disease beyond 20 years. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 849-855.	0.9	55
44	Mutant <i>COQ2</i> in Multiple-System Atrophy. <i>New England Journal of Medicine</i> , 2014, 371, 80-83.	13.9	81
45	The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. <i>Brain</i> , 2014, 137, 2731-2742.	3.7	251
46	Swallowing disturbances in Parkinson's disease: A multivariate analysis of contributing factors. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1382-1387.	1.1	93
47	Novel <i>DYT11</i> gene mutation in patients without dopaminergic deficit (SWEDD) screened for dystonia. <i>Neurology</i> , 2014, 83, 1155-1162.	1.5	22
48	Reversible dopamine transporter reduction in drug-induced parkinsonism. <i>Movement Disorders</i> , 2014, 29, 575-577.	2.2	16
49	<i>LRRK2</i> G2019S mutation is not associated with an increased cancer risk: A kin cohort study. <i>Movement Disorders</i> , 2014, 29, 1325-1326.	2.2	11
50	Glucocerebrosidase mutations in primary parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1215-1220.	1.1	63
51	Later age at onset in Parkinson's disease over twenty years in an Italian tertiary clinic. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 1181-1185.	1.1	3
52	Multiple compulsive behaviors in multiple system atrophy: The importance of predisposition to addiction. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 355-357.	1.1	8
53	Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 311-318.	0.9	57
54	<i>LRRK2</i> mutations in Parkinson's disease: Confirmation of a gender effect in the Italian population. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 911-914.	1.1	40

#	ARTICLE	IF	CITATIONS
55	Impulse Control Disorders are Associated with Multiple Psychiatric Symptoms in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2014, 4, 507-515.	1.5	10
56	Do Tardive Dyskinesia and L-Dopa Induced Dyskinesia Share Common Genetic Risk Factors? An Exploratory Study. <i>Journal of Molecular Neuroscience</i> , 2013, 51, 380-388.	1.1	12
57	Nutritional status and dietary habits in Parkinson's disease patients in Ghana. <i>Nutrition</i> , 2013, 29, 470-473.	1.1	14
58	DJ1 analysis in a large cohort of Italian early onset Parkinson Disease patients. <i>Neuroscience Letters</i> , 2013, 557, 165-170.	1.0	11
59	Cardiometabolic factors and disease duration in patients with Parkinson's disease. <i>Nutrition</i> , 2013, 29, 1331-1335.	1.1	24
60	Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: A SPECT follow-up study. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 557-559.	1.1	33
61	Association of nicotine dependence susceptibility gene, CHRNA5, with Parkinson's disease age at onset: Gene and smoking status interaction. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 72-76.	1.1	21
62	No association of <i>GBA</i> mutations and multiple system atrophy. <i>European Journal of Neurology</i> , 2013, 20, e61-2.	1.7	28
63	Meningioma with intense <sup>123</sup> I-FP-CIT uptake. <i>Movement Disorders</i> , 2012, 27, 1744-1745.	2.2	3
64	The relationship between cerebral vascular disease and parkinsonism: The VADO study. <i>Parkinsonism and Related Disorders</i> , 2012, 18, 775-780.	1.1	58
65	How neurodegeneration, dopamine and maladaptive behavioral learning interact to produce impulse control disorders in Parkinson's disease. <i>Basal Ganglia</i> , 2012, 2, 195-199.	0.3	3
66	Diagnostic agreement in patients with psychogenic movement disorders. <i>Movement Disorders</i> , 2012, 27, 548-552.	2.2	60
67	The Asp620asn mutation in VPS35 is not a common cause of familial Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 800-801.	2.2	15
68	Screening LRRK2 gene mutations in patients with Parkinson's disease in Ghana. <i>Journal of Neurology</i> , 2012, 259, 569-570.	1.8	24
69	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. <i>Nature Genetics</i> , 2011, 43, 699-705.	9.4	502
70	Cortical visual evoked potentials recorded after optic tract near field stimulation during GPI-DBS in non-cooperative patients. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 119-122.	0.6	9
71	Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. <i>PLoS ONE</i> , 2011, 6, e18301.	1.1	84
72	Parkinson's disease in sub-Saharan Africa: step-by-step into the challenge. <i>Neurodegenerative Disease Management</i> , 2011, 1, 193-202.	1.2	11

#	ARTICLE	IF	CITATIONS
73	Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding. <i>Brain Structure and Function</i> , 2011, 216, 289-299.	1.2	72
74	Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: A path modeling analysis. <i>Movement Disorders</i> , 2011, 26, 225-233.	2.2	109
75	Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 464-468.	2.2	139
76	Cognitive status of patients with Parkinson's disease and pathological gambling. <i>Journal of Neurology</i> , 2010, 257, 247-252.	1.8	49
77	Psychiatric symptoms in Parkinson's disease assessed with the SCL-90R self-reported questionnaire. <i>Neurological Sciences</i> , 2010, 31, 35-40.	0.9	40
78	Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. <i>Neurobiology of Disease</i> , 2010, 39, 98-104.	2.1	136
79	Continuous theta burst stimulation of right dorsolateral prefrontal cortex induces changes in impulsivity level. <i>Brain Stimulation</i> , 2010, 3, 170-176.	0.7	150
80	Surgical, Medical, and Hardware Adverse Events in a Series of 141 Patients Undergoing Subthalamic Deep Brain Stimulation for Parkinson Disease. <i>World Neurosurgery</i> , 2010, 73, 338-344.	0.7	77
81	Imaging essential tremor. <i>Movement Disorders</i> , 2010, 25, 679-686.	2.2	80
82	A Novel Polymorphic AP-1 Binding Element of the <i>GFAP</i> Promoter is Associated with Different Allelic Transcriptional Activities. <i>Annals of Human Genetics</i> , 2010, 74, 506-515.	0.3	14
83	Sleep in Genetically Confirmed Pantothenate Kinase-Associated Neurodegeneration: A Video-Polysomnographic Study. <i>Parkinson's Disease</i> , 2010, 2010, 1-4.	0.6	9
84	Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. <i>Neurology</i> , 2010, 75, 1711-1716.	1.5	191
85	Cerebral blood flow changes induced by pedunculo-pontine nucleus stimulation in patients with advanced Parkinson's disease: A [ <sup>15</sup> O] H <sub>2</sub> O PET study. <i>Human Brain Mapping</i> , 2009, 30, 3901-3909.	1.9	99
86	Clinical and cerebral activity changes induced by subthalamic nucleus stimulation in advanced Parkinson's disease: A prospective case-control study. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 140-146.	0.6	40
87	Behavioural Adverse Effects of Dopaminergic Treatments in Parkinson's Disease. <i>Drug Safety</i> , 2009, 32, 475-488.	1.4	80
88	Screening for the Presence of FMR1 Premutation Alleles in Women With Parkinsonism. <i>Archives of Neurology</i> , 2009, 66, 244-9.	4.9	27
89	Cerebral activity modulation by extradural motor cortex stimulation in Parkinson's disease: a perfusion SPECT study. <i>European Journal of Neurology</i> , 2008, 15, 22-28.	1.7	18
90	The relationship between impulsivity and impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 411-415.	2.2	131

#	ARTICLE	IF	CITATIONS
91	Parkin analysis in early onset Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 326-333.	1.1	42
92	Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease. <i>Archives of Neurology</i> , 2008, 65, 1604-11.	4.9	127
93	Striatal dopamine transporter abnormalities in patients with essential tremor. <i>Nuclear Medicine Communications</i> , 2008, 29, 349-353.	0.5	69
94	Screen for Excess FMR1 Premutation Alleles Among Males With Parkinsonism. <i>Archives of Neurology</i> , 2007, 64, 1002.	4.9	33
95	[123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. <i>NeuroReport</i> , 2007, 18, 1499-1502.	0.6	59
96	Anatomical identification of active contacts in subthalamic deep brain stimulation. <i>World Neurosurgery</i> , 2007, 67, 140-146.	1.3	35
97	Brain networks underlining verbal fluency decline during STN-DBS in Parkinson's disease: An ECD-SPECT study. <i>Parkinsonism and Related Disorders</i> , 2007, 13, 290-294.	1.1	61
98	Third cranial nerve palsy? Look for a sicca syndrome. <i>Journal of the Neurological Sciences</i> , 2007, 253, 88-89.	0.3	8
99	Extradural motor cortex stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 111-114.	2.2	46
100	Striatal dopamine transporter binding in patients with Parkinson's disease and severe occupational hydrocarbon exposure. <i>European Journal of Neurology</i> , 2007, 14, 070206022829003-???	1.7	11
101	Clinical and imaging characterization of a patient with idiopathic progressive ataxia and palatal tremor. <i>European Journal of Neurology</i> , 2007, 14, 944-946.	1.7	14
102	LRRK2 G2019S mutation and Parkinson's disease: A clinical, neuropsychological and neuropsychiatric study in a large Italian sample. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 410-419.	1.1	106
103	Genetic, clinical, and imaging characterization of one patient with late-onset, slowly progressive, pantothenate kinase-associated neurodegeneration. <i>Movement Disorders</i> , 2006, 21, 417-418.	2.2	28
104	Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. <i>Movement Disorders</i> , 2006, 21, 1144-1147.	2.2	41
105	Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 450-453.	0.9	130
106	Brain SPECT imaging in multiple system atrophy. <i>Journal of Neural Transmission</i> , 2005, 112, 1635-1645.	1.4	50